Since the advent of tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) has been transformed from a disease that was usually fatal into one in which patients have a close-to-normal life expectancy. In some cases, the response to treatment is sufficiently prolonged and deep that patients may be able to discontinue their medication. Is this a good idea? In this month's Counterpoints, Drs Nicholas Short and Elias Jabbour argue for the continued treatment of CML, whereas Drs Gabriel Etienne and François-Xavier Mahon make the case for treatment discontinuation.
Counterpoints: Should Treatment for CML Continue Indefinitely?
1 reply to this topic
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users